|
|
| (12 intermediate revisions by 5 users not shown) |
| Line 1: |
Line 1: |
| {{CMG}}
| | #REDIRECT [[Fondaparinux#Contraindications]] |
|
| |
|
| | | [[Category: Cardiovascular Drugs]] |
| '''Fondaparinux sodium''' (Arixtra) Injection is contraindicated in patients with severe renal impairment (creatinine clearance <30 mL/min). Fondaparinux sodium (Arixtra) is eliminated primarily by the kidneys, and such patients are at increased risk for major bleeding episodes.
| | [[Category: Drug]] |
| | | [[Category: Anticoagulants]] |
| Fondaparinux sodium (Arixtra) prophylactic therapy is contraindicated in patients with body weight <50 kg undergoing hip fracture, hip replacement or knee replacement surgery, and abdominal surgery. During the randomized clinical trials of prophylaxis in the peri-operative period following hip fracture, hip replacement, or knee replacement surgery, occurrence of major bleeding was doubled in patients with a body weight <50 kg compared with those with a body weight ≥50 kg (5.4% versus 2.1%). In the clinical trial in patients undergoing abdominal surgery, the major bleeding rate was also higher in patients with a body weight <50 kg as compared to those with a body weight ≥50 kg (5.3% versus 3.3%), respectively.
| |
| | |
| The use of Fondaparinux sodium (Arixtra) is contraindicated in patients with active major bleeding, [[bacterial endocarditis]], in patients with thrombocytopenia associated with a positive in vitro test for anti-platelet antibody in the presence of fondaparinux sodium, or in patients with known hypersensitivity to fondaparinux sodium.
| |